Clinical Trial Update: Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating neoadjuvant therapy for locally advanced rectal cancer using radiotherapy with CAPOX and immune agents iparomlimab and tuvonralimab (QL…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Tuvonralimab (QL1706)
• iparomlimab

Snippet

Sponsor: Zhongnan Hospital | Conditions: Rectal Cancer Patients | Phase 2 | Status: NOT_YET_RECRUITING